Literature DB >> 15388579

UGT1A1 variation and gallstone formation in sickle cell disease.

Eden V Haverfield1, Colin A McKenzie, Terrence Forrester, Nourdine Bouzekri, Rosalind Harding, Graham Serjeant, Thomas Walker, Tim E A Peto, Ryk Ward, David J Weatherall.   

Abstract

Pigment gallstones are a common clinical complication of sickle cell (SS) disease. Genetic variation in the promoter of uridine diphosphate (UDP)-glucuronosyltransferase 1A1 (UGT1A1) underlies Gilbert syndrome, a chronic form of unconjugated hyperbilirubinemia, and appears to be a risk factor for gallstone formation. We investigated the association between UGT1A1 (TA)(n) genotype, hyperbilirubinemia, and gallstones in a sample of Jamaicans with SS disease. Subjects were from the Jamaican Sickle Cell Cohort Study (cohort sample, n = 209) and the Sickle Cell Clinic at the University of the West Indies, Kingston, Jamaica (clinic sample, n = 357). The UGT1A1 (TA)(n) promoter region was sequenced in 541 SS disease subjects and 111 healthy controls (control sample). Indirect bilirubin levels for (TA)(7)/(TA)(7) and (TA)(7)/(TA)(8) genotypes were elevated compared with (TA)(6)/(TA)(6) (clinic sample, P < 10(-5); cohort sample, P < 10(-3)). The (TA)(7)/(TA)(7) genotype was also associated with symptomatic presentation and gallstones in the clinic sample (odds ratio [OR] = 11.3; P = 7.0 x 10(-4)) but not in the younger cohort sample. These unexpected findings indicate that the temporal evolution of symptomatic gallstones may involve factors other than the bilirubin level. Although further studies of the pathogenesis of gallstones in SS disease are required, the (TA)(7)/(TA)(7) genotype may be a risk factor for symptomatic gallstones in older people with SS disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15388579     DOI: 10.1182/blood-2004-02-0521

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  20 in total

Review 1.  Gilbert syndrome.

Authors:  Andrew Fretzayas; Maria Moustaki; Olga Liapi; Themistocles Karpathios
Journal:  Eur J Pediatr       Date:  2011-12-09       Impact factor: 3.183

Review 2.  Pharmacogenetic research activity in Central America and the Caribbean: a systematic review.

Authors:  Carolina Céspedes-Garro; María-Eugenia G Naranjo; Fernanda Rodrigues-Soares; Adrián LLerena; Jorge Duconge; Lazara K Montané-Jaime; Hilda Roblejo; Humberto Fariñas; María de Los A Campos; Ronald Ramírez; Víctor Serrano; Carmen I Villagrán; Eva M Peñas-LLedó
Journal:  Pharmacogenomics       Date:  2016-09-16       Impact factor: 2.533

Review 3.  The search for genetic modifiers of disease severity in the β-hemoglobinopathies.

Authors:  Guillaume Lettre
Journal:  Cold Spring Harb Perspect Med       Date:  2012-10-01       Impact factor: 6.915

Review 4.  Minireview: Clinical severity in sickle cell disease: the challenges of definition and prognostication.

Authors:  Charles T Quinn
Journal:  Exp Biol Med (Maywood)       Date:  2016-03-23

5.  Influence of UGT1A1 promoter polymorphism, α-thalassemia and βs haplotype in bilirubin levels and cholelithiasis in a large sickle cell anemia cohort.

Authors:  Jéssica V G F Batista; Gabriela S Arcanjo; Thais H C Batista; Marcondes J Sobreira; Rodrigo M Santana; Igor F Domingos; Betânia L Hatzlhofer; Diego A Falcão; Diego A Pereira-Martins; Jéssica M Oliveira; Amanda S Araujo; Luana P M Laranjeira; Fernanda S Medeiros; Flávia P Albuquerque; Dulcinéia M Albuquerque; Magnun N Santos; Manuela F Hazin; Ana C Dos Anjos; Fernando F Costa; Aderson S Araujo; Antonio R Lucena-Araujo; Marcos A Bezerra
Journal:  Ann Hematol       Date:  2021-02-01       Impact factor: 3.673

6.  Do Alpha Thalassemia, Fetal Hemoglobin, and the UGT1A1 Polymorphism have an Influence on Serum Bilirubin Levels and Cholelithiasis in Patients with Sickle Cell Disease?

Authors:  Laura Alencastro de Azevedo; Joyce Bonazzoni; Sandrine Comparsi Wagner; Mariela Granero Farias; Christina M Bittar; Liane Daudt; Simone Martins de Castro
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

7.  Sickle Cell Disease in the Post Genomic Era: A Monogenic Disease with a Polygenic Phenotype.

Authors:  A Driss; K O Asare; J M Hibbert; B E Gee; T V Adamkiewicz; J K Stiles
Journal:  Genomics Insights       Date:  2009-07-30

Review 8.  PharmGKB summary: very important pharmacogene information for UGT1A1.

Authors:  Julia M Barbarino; Cyrine E Haidar; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2014-03       Impact factor: 2.089

9.  Early modification of sickle cell disease clinical course by UDP-glucuronosyltransferase 1A1 gene promoter polymorphism.

Authors:  Rute Martins; Anabela Morais; Alexandra Dias; Isabel Soares; Cristiana Rolão; J L Ducla-Soares; Lígia Braga; Teresa Seixas; Baltazar Nunes; Gabriel Olim; Luísa Romão; João Lavinha; Paula Faustino
Journal:  J Hum Genet       Date:  2008-04-05       Impact factor: 3.172

10.  A polygenic score for acute vaso-occlusive pain in pediatric sickle cell disease.

Authors:  Evadnie Rampersaud; Guolian Kang; Lance E Palmer; Sara R Rashkin; Shuoguo Wang; Wenjian Bi; Nicole M Alberts; Doralina Anghelescu; Martha Barton; Kirby Birch; Nidal Boulos; Amanda M Brandow; Russell John Brooke; Ti-Cheng Chang; Wenan Chen; Yong Cheng; Juan Ding; John Easton; Jason R Hodges; Celeste K Kanne; Shawn Levy; Heather Mulder; Ashwin P Patel; Latika Puri; Celeste Rosencrance; Michael Rusch; Yadav Sapkota; Edgar Sioson; Akshay Sharma; Xing Tang; Andrew Thrasher; Winfred Wang; Yu Yao; Yutaka Yasui; Donald Yergeau; Jane S Hankins; Vivien A Sheehan; James R Downing; Jeremie H Estepp; Jinghui Zhang; Michael DeBaun; Gang Wu; Mitchell J Weiss
Journal:  Blood Adv       Date:  2021-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.